Logo image of ERAS

ERASCA INC (ERAS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ERAS - US29479A1088 - Common Stock

2.89 USD
-0.11 (-3.67%)
Last: 12/2/2025, 4:30:02 PM
2.89 USD
0 (0%)
After Hours: 12/2/2025, 4:30:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ERAS. ERAS was compared to 534 industry peers in the Biotechnology industry. While ERAS has a great health rating, there are worries on its profitability. ERAS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ERAS had negative earnings in the past year.
ERAS had a negative operating cash flow in the past year.
In the past 5 years ERAS always reported negative net income.
In the past 5 years ERAS always reported negative operating cash flow.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ERAS's Return On Assets of -28.80% is fine compared to the rest of the industry. ERAS outperforms 68.54% of its industry peers.
ERAS's Return On Equity of -34.46% is fine compared to the rest of the industry. ERAS outperforms 74.16% of its industry peers.
Industry RankSector Rank
ROA -28.8%
ROE -34.46%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ERAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ERAS has more shares outstanding
ERAS has more shares outstanding than it did 5 years ago.
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ERAS has an Altman-Z score of 4.10. This indicates that ERAS is financially healthy and has little risk of bankruptcy at the moment.
ERAS has a Altman-Z score of 4.10. This is in the better half of the industry: ERAS outperforms 71.91% of its industry peers.
There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.1
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ERAS has a Current Ratio of 11.04. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
ERAS has a Current ratio of 11.04. This is amongst the best in the industry. ERAS outperforms 84.64% of its industry peers.
ERAS has a Quick Ratio of 11.04. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
ERAS has a Quick ratio of 11.04. This is amongst the best in the industry. ERAS outperforms 84.64% of its industry peers.
Industry RankSector Rank
Current Ratio 11.04
Quick Ratio 11.04
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.78% over the past year.
EPS 1Y (TTM)45.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.80% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.66%
EPS Next 2Y17.14%
EPS Next 3Y9.71%
EPS Next 5Y9.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERAS. In the last year negative earnings were reported.
Also next year ERAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.14%
EPS Next 3Y9.71%

More info and screens

0

5. Dividend

5.1 Amount

ERAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERASCA INC

NASDAQ:ERAS (12/2/2025, 4:30:02 PM)

After market: 2.89 0 (0%)

2.89

-0.11 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners73.92%
Inst Owner Change-2.33%
Ins Owners7.34%
Ins Owner Change0%
Market Cap819.92M
Revenue(TTM)N/A
Net Income(TTM)-128.27M
Analysts81.25
Price Target5.21 (80.28%)
Short Float %7.13%
Short Ratio8.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.73%
Min EPS beat(2)-6.95%
Max EPS beat(2)14.41%
EPS beat(4)3
Avg EPS beat(4)13.95%
Min EPS beat(4)-6.95%
Max EPS beat(4)35.3%
EPS beat(8)5
Avg EPS beat(8)1.58%
EPS beat(12)8
Avg EPS beat(12)-13.31%
EPS beat(16)10
Avg EPS beat(16)-10.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.22%
PT rev (3m)2.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.92%
EPS NY rev (1m)0%
EPS NY rev (3m)1.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.8%
ROE -34.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.04
Quick Ratio 11.04
Altman-Z 4.1
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.09%
Cap/Depr(5y)425.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y39.66%
EPS Next 2Y17.14%
EPS Next 3Y9.71%
EPS Next 5Y9.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.82%
EBIT Next 3Y2.17%
EBIT Next 5Y1.37%
FCF growth 1Y7.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERASCA INC / ERAS FAQ

Can you provide the ChartMill fundamental rating for ERASCA INC?

ChartMill assigns a fundamental rating of 3 / 10 to ERAS.


Can you provide the valuation status for ERASCA INC?

ChartMill assigns a valuation rating of 0 / 10 to ERASCA INC (ERAS). This can be considered as Overvalued.


What is the profitability of ERAS stock?

ERASCA INC (ERAS) has a profitability rating of 1 / 10.